Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 01, 2008 (Vol. 28, No. 3)

GNF SymAtlas

URL:symatlas.gnf.org/SymAtlas
  • Fast search engine
  • Interface needs some work
As noted at the site, “SymAtlas is a web-application for publishing experimental gene functionalization datasets integrated with a flexibly searchable gene-centric database of public and proprietary annotations.” Hosted by the Genomics Institute of the Novartis Research Foundation, GNF SymAtlas provides access to an RNA expression database with numerous options for searching and hyperlinked subtext within the returned results. The interface is a little awkward (pop-up text when mousing over program options) and two sections to search text in the search window. It is not clear why these were not merged into one. Searches can be limited by species, keyword, author, and more. Returned results are extensively hyperlinked, so be prepared to do a lot of clicking to find what you’re after.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »